Logotipo del repositorio
Logotipo del repositorio
 

Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2eng
dc.contributor.authorSalazar, Juan
dc.contributor.authorPirela, Daniela
dc.contributor.authorNava, Manuel
dc.contributor.authorCastro, Ana
dc.contributor.authorAngarita, Lissé
dc.contributor.authorParra, Heliana
dc.contributor.authorDurán-Agüero, Samuel
dc.contributor.authorRojas-Gómez, Diana Marcela
dc.contributor.authorGalbán, Néstor
dc.contributor.authorAñez, Roberto
dc.contributor.authorChacín, Maricarmen
dc.contributor.authorDiaz, Andrea
dc.contributor.authorVillasmil, Nelson
dc.contributor.authorBautista De Sanctis, Juan
dc.contributor.authorBermúdez, Valmore
dc.date.accessioned2022-11-10T13:31:14Z
dc.date.available2022-11-10T13:31:14Z
dc.date.issued2022
dc.description.abstractCardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.eng
dc.format.mimetypepdfspa
dc.identifier.citationSalazar, J., Pirela, D., Nava, M., Castro, A., Angarita, L., Parra, H., Durán-Agüero, S., Rojas-Gómez, D. M., Galbán, N., Añez, R., Chacín, M., Diaz, A., Villasmil, N., De Sanctis, J. B., & Bermúdez, V. (2022). Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis. International Journal of Molecular Sciences, 23(6), 3133. https://doi.org/10.3390/ijms23063133eng
dc.identifier.doihttps://doi.org/10.3390/ijms23063133
dc.identifier.issn14220067
dc.identifier.urihttps://hdl.handle.net/20.500.12442/11286
dc.language.isoengeng
dc.publisherMDPIeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceInternational Journal of Molecular Scienceseng
dc.sourceVol. 23, No.6 (2022)
dc.subjectspecialized proresolving mediatorseng
dc.subjectinflammationeng
dc.subjectresolutioneng
dc.subjectAtherosclerosiseng
dc.subjectIntimal hyperplasiaeng
dc.subjectReperfusion injuryeng
dc.titleSpecialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosiseng
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
dcterms.referencesCapó, X.; Martorell, M.; Busquets-Cortés, C.; Tejada, S.; Tur, J.A.; Pons, A.; Sureda, A. Resolvins as proresolving inflammatory mediators in cardiovascular disease. Eur. J. Med. Chem. 2018, 153, 123–130. [CrossRef] [PubMed]eng
dcterms.referencesWorld Health Organization. Cardiovascular Diseases (CVDs). Available online: https://www.who.int/news-room/fact-sheets/ detail/cardiovascular-diseases-(cvds) (accessed on 18 August 2021).eng
dcterms.referencesMorales Aguilar, R.; Lastre-Amell, G.; Pardo Vásquez, A. Estilos de vida relacionados con factores de riesgo cardiovascular. AVFT Arch. Venez. Farm. Ter. 2018, 37, 50–62.spa
dcterms.referencesRecchiuti, A.; Serhan, C.N. Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. Front. Immunol. 2012, 3, 298. [CrossRef] [PubMed]eng
dcterms.referencesSugimoto, M.A.; Sousa, L.P.; Pinho, V.; Perretti, M.; Teixeira, M.M. Resolution of Inflammation: What Controls Its Onset? Front. Immunol. 2016, 7, 160. [CrossRef]eng
dcterms.referencesNathan, C.; Ding, A. Nonresolving Inflammation. Cell 2010, 140, 871–882. [CrossRef]eng
dcterms.referencesHeadland, S.E.; Norling, L.V. The resolution of inflammation: Principles and challenges. Semin. Immunol. 2015, 27, 149–160. [CrossRef]eng
dcterms.referencesSerhan, C.N.; Chiang, N.; Van Dyke, T.E. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8, 349–361. [CrossRef]eng
dcterms.referencesBuckley, C.D.; Gilroy, D.W.; Serhan, C.N. Pro-Resolving lipid mediators and Mechanisms in the resolution of acute inflammation. Immunity 2014, 40, 315–327. [CrossRef]eng
dcterms.referencesBasil, M.C.; Levy, B.D. Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation. Nat. Rev. Immunol. 2016, 16, 51–67. [CrossRef]eng
dcterms.referencesPark, J.; Langmead, C.J.; Riddy, D.M. New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery. ACS Pharmacol. Transl. Sci. 2020, 3, 88–106. [CrossRef]eng
dcterms.referencesDoran, A.C. Inflammation Resolution: Implications for Atherosclerosis. Circ. Res. 2022, 130, 130–148. [CrossRef]eng
dcterms.referencesde Gaetano, M.; McEvoy, C.; Andrews, D.; Cacace, A.; Hunter, J.; Brennan, E.; Godson, C. Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications. Front. Pharmacol. 2018, 9, 1488. [CrossRef] [PubMed]eng
dcterms.referencesDoyle, R.; Sadlier, D.M.; Godson, C. Pro-resolving lipid mediators: Agents of anti-ageing? Semin. Immunol. 2018, 40, 36–48. [CrossRef] [PubMed]eng
dcterms.referencesViola, J.R.; Lemnitzer, P.; Jansen, Y.; Csaba, G.; Winter, C.; Neideck, C.; Silvestre-Roig, C.; Dittmar, G.; Döring, Y.; Drechsler, M.; et al. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice. Circ. Res. 2016, 119, 1030–1038. [CrossRef] [PubMed]eng
dcterms.referencesFredman, G.; Spite, M. Specialized pro-resolving mediators in cardiovascular diseases. Mol. Asp. Med. 2017, 58, 65–71. [CrossRef]eng
dcterms.referencesKasikara, C.; Doran, A.C.; Cai, B.; Tabas, I. The role of non-resolving inflammation in atherosclerosis. J. Clin. Investig. 2018, 128, 2713–2723. [CrossRef]eng
dcterms.referencesSatish, M.; Agrawal, D.K. Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases. Expert Rev. Cardiovasc. Ther. 2019, 17, 177–184. [CrossRef]eng
dcterms.referencesHalade, G.V.; Black, L.M.; Verma, M. Paradigm shift—Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery. Biotechnol. Adv. 2018, 36, 935–953. [CrossRef]eng
dcterms.referencesHalade, G.V.; Kain, V.; Ingle, K.A.; Prabhu, S.D. Interaction of 12/15-lipoxygenase with fatty acids alters the leukocyte kinetics leading to improved postmyocardial infarction healing. Am. J. Physiol. Heart Circ. Physiol. 2017, 313, H89–H102. [CrossRef]eng
dcterms.referencesHalade, G.V.; Kain, V.; Tourki, B.; Jadapalli, J.K. Lipoxygenase drives lipidomic and metabolic reprogramming in ischemic heart failure. Metabolism 2019, 96, 22–32. [CrossRef]eng
dcterms.referencesChiang, N.; Serhan, C.N. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol. Asp. Med. 2017, 58, 114–129. [CrossRef] [PubMed]eng
dcterms.referencesBang, S.; Xie, Y.-K.; Zhang, Z.-J.; Wang, Z.; Xu, Z.-Z.; Ji, R.-R. GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain. J. Clin. Investig. 2018, 128, 3568–3582. [CrossRef] [PubMed]eng
dcterms.referencesDalli, J.; Serhan, C.N. Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. Br. J. Pharmacol. 2019, 176, 1024–1037. [CrossRef] [PubMed]eng
dcterms.referencesDalli, J.; Serhan, C.N. Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. Br. J. Pharmacol. 2019, 176, 1024–1037. [CrossRef] [PubMed]eng
dcterms.referencesHan, Y.-H.; Lee, K.; Saha, A.; Han, J.; Choi, H.; Noh, M.; Lee, Y.-H.; Lee, M.-O. Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders. Biomol. Ther. 2021, 29, 455–464. [CrossRef]eng
dcterms.referencesKang, G.J.; Kim, E.J.; Lee, C.H. Therapeutic Effects of Specialized Pro-Resolving Lipids Mediators on Cardiac Fibrosis via NRF2 Activation. Antioxidants 2020, 9, 1259. [CrossRef]eng
dcterms.referencesRecchiuti, A. Resolvin D1 and its GPCRs in resolution circuits of inflammation. Prostaglandins Other Lipid Mediat. 2013, 107, 64–76.eng
dcterms.referencesMcCrary, M.R.; Jiang, M.Q.; Giddens, M.M.; Zhang, J.Y.; Owino, S.; Wei, Z.Z.; Zhong, W.; Gu, X.; Xin, H.; Hall, R.A.; et al. Protective effects of GPR37 via regulation of inflammation and multiple cell death pathways after ischemic stroke in mice. FASEB J. 2019, 33, 10680–10691.eng
dcterms.referencesMcCrary, M.R.; Jiang, M.Q.; Giddens, M.M.; Zhang, J.Y.; Owino, S.; Wei, Z.Z.; Zhong, W.; Gu, X.; Xin, H.; Hall, R.A.; et al. Protective effects of GPR37 via regulation of inflammation and multiple cell death pathways after ischemic stroke in mice. FASEB J. 2019, 33, 10680–10691.eng
dcterms.referencesDalli, J.; Serhan, C.N. Pro-Resolving Mediators in Regulating and Conferring Macrophage Function. Front. Immunol. 2017, 8, 1400.eng
dcterms.referencesDalli, J.; Serhan, C.N. Pro-Resolving Mediators in Regulating and Conferring Macrophage Function. Front. Immunol. 2017, 8, 1400. [CrossRef]eng
dcterms.referencesYokomizo, T. Two distinct leukotriene B4 receptors, BLT1 and BLT2. J. Biochem. 2015, 157, 65–71. [CrossRef]eng
dcterms.referencesColas, R.A.; Dalli, J.; Chiang, N.; Vlasakov, I.; Sanger, J.M.; Riley, I.R.; Serhan, C.N. Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation. J. Immunol. 2016, 197, 4444–4452. [CrossRef]eng
dcterms.referencesChiang, N.; Libreros, S.; Norris, P.C.; De La Rosa, X.; Serhan, C.N. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. J. Clin. Investig. 2019, 129, 5294–5311. [CrossRef] [PubMed]eng
dcterms.referencesFlak, M.B.; Koenis, D.S.; Sobrino, A.; Smith, J.; Pistorius, K.; Palmas, F.; Dalli, J. GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections. J. Clin. Investig. 2020, 130, 359–373. [CrossRef] [PubMed]eng
dcterms.referencesChattopadhyay, R.; Mani, A.M.; Singh, N.K.; Rao, G.N. Resolvin D1 blocks H2O2-mediated inhibitory crosstalk between SHP2 and PP2A and suppresses endothelial-monocyte interactions. Free Radic. Biol. Med. 2018, 117, 119–131. [CrossRef] [PubMed]eng
dcterms.referencesChattopadhyay, R.; Raghavan, S.; Rao, G.N. Resolvin D1 via prevention of ROS-mediated SHP2 inactivation protects endothelial adherens junction integrity and barrier function. Redox Biol. 2017, 12, 438–455. [CrossRef]eng
dcterms.referencesCarracedo, M.; Artiach, G.; Arnardottir, H.; Bäck, M. The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Semin. Immunopathol. 2019, 41, 757–766. [CrossRef]eng
dcterms.referencesKrishnamoorthy, S.; Recchiuti, A.; Chiang, N.; Yacoubian, S.; Lee, C.-H.; Yang, R.; Petasis, N.A.; Serhan, C.N. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 2010, 107, 1660–1665. [CrossRef]eng
dcterms.referencesSo, J.; Wu, D.; Lichtenstein, A.H.; Tai, A.K.; Matthan, N.R.; Maddipati, K.R.; Lamon-Fava, S. EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study. Atherosclerosis 2020, 316, 90–98. [CrossRef]eng
dcterms.referencesLopez, E.F.; Kabarowski, J.H.; Ingle, K.A.; Kain, V.; Barnes, S.; Crossman, D.; Lindsey, M.; Halade, G.V. Obesity superimposed on aging magnifies inflammation and delays the resolving response after myocardial infarction. Am. J. Physiol. Circ. Physiol. 2015, 308, H269–H280. [CrossRef]eng
dcterms.referencesHalade, G.V.; Kain, V.; Black, L.M.; Prabhu, S.D.; Ingle, K.A. Aging dysregulates D- and E-series resolvins to modulate cardios- plenic and cardiorenal network following myocardial infarction. Aging 2016, 8, 2611–2634. [CrossRef]eng
dcterms.referencesJadapalli, J.K.; Wright, G.W.; Kain, V.; Sherwani, M.A.; Sonkar, R.; Yusuf, N.; Halade, G.V. Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium. Am. J. Physiol. Circ. Physiol. 2018, 315, H1091–H1100. [CrossRef]eng
dcterms.referencesHalade, G.V.; Kain, V.; Wright, G.M.; Jadapalli, J.K. Subacute treatment of carprofen facilitate splenocardiac resolution deficit in cardiac injury. J. Leukoc. Biol. 2018, 104, 1173–1186. [CrossRef] [PubMed]eng
dcterms.referencesKain, V.; Jadapalli, J.K.; Tourki, B.; Halade, G.V. Inhibition of FPR2 impaired leukocytes recruitment and elicited non-resolving inflammation in acute heart failure. Pharmacol. Res. 2019, 146, 104295. [CrossRef] [PubMed]eng
dcterms.referencesBrennan, E.; Kantharidis, P.; Cooper, M.E.; Godson, C. Pro-resolving lipid mediators: Regulators of inflammation, metabolism and kidney function. Nat. Rev. Nephrol. 2021, 17, 725–739. [CrossRef] [PubMed]eng
dcterms.referencesJadapalli, J.K.; Halade, G.V. Unified nexus of macrophages and maresins in cardiac reparative mechanisms. FASEB J. 2018, 32, 5227–5237. [CrossRef] [PubMed]eng
dcterms.referencesChandrasekharan, J.A.; Sharma-Walia, N. Lipoxins: Nature’s way to resolve inflammation. J. Inflamm. Res. 2015, 8, 181–192.eng
dcterms.referencesHo, K.J.; Spite, M.; Owens, C.D.; Lancero, H.; Kroemer, A.H.; Pande, R.; Creager, M.A.; Serhan, C.N.; Conte, M.S. Aspirin- Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. Am. J. Pathol. 2010, 177, 2116–2123. [CrossRef]eng
dcterms.referencesHo, K.J.; Spite, M.; Owens, C.D.; Lancero, H.; Kroemer, A.H.; Pande, R.; Creager, M.A.; Serhan, C.N.; Conte, M.S. Aspirin- Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. Am. J. Pathol. 2010, 177, 2116–2123. [CrossRef]eng
dcterms.referencesRafieian-Kopaei, M.; Setorki, M.; Doudi, M.; Baradaran, A.; Nasri, H. Atherosclerosis: Process, Indicators, Risk Factors and New Hopes. Int. J. Prev. Med. 2014, 5, 927–946.eng
dcterms.referencesVerónica Mora, D.E.; Morr, C.; Paciotti, S.; Prospert, O.P.; Quiroz, J. Células inflamatorias en lesiones ateroescleróticas de las arterias coronarias humanas. Gac. Médica Caracas 2020, 124, 298–307.spa
dcterms.referencesFredman, G.; Tabas, I. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am. J. Pathol. 2017, 187, 1211–1221. [CrossRef]eng
dcterms.referencesRojas, J.; Salazar, J.; Martínez, M.S.; Palmar, J.; Bautista, J.; Chávez-Castillo, M.; Gómez, A.; Bermudez, V. Macrophage Heterogene- ity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis. Scientifica 2015, 2015, 1–17. [CrossRef]eng
dcterms.referencesViola, J.; Soehnlein, O. Atherosclerosis—A matter of unresolved inflammation. Semin. Immunol. 2015, 27, 184–193. [CrossRef] [PubMed]eng
dcterms.referencesSansbury, B.E.; Spite, M. Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology. Circ. Res. 2016, 119, 113–130. [CrossRef] [PubMed]eng
dcterms.referencesKain, V.; Van Der Pol, W.; Mariappan, N.; Ahmad, A.; Eipers, P.; Morrow, C.; Gibson, D.L.; Gladine, C.; Vigor, C.; Durand, T.; et al. Obesogenic diet in aging mice disrupts gut microbe composition and alters neutrophil:lymphocyte ratio leading to inflamed milieu in acute heart failure. FASEB J. 2019, 33, 6456–6469. [CrossRef]eng
dcterms.referencesChatterjee, A.; Sharma, A.; Chen, M.; Toy, R.; Mottola, G.; Conte, M.S. The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells. PLoS ONE 2014, 9, e113480. [CrossRef]eng
dcterms.referencesCherpokova, D.; Jouvene, C.C.; Libreros, S.; DeRoo, E.P.; Chu, L.; De La Rosa, X.; Norris, P.C.; Wagner, D.D.; Serhan, C.N. Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood 2019, 134, 1458–1468. [CrossRef] [PubMed]eng
dcterms.referencesMiyahara, T.; Runge, S.; Chatterjee, A.; Chen, M.; Mottola, G.; Fitzgerald, J.M.; Serhan, C.N.; Conte, M.S. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 2013, 27, 2220–2232. [CrossRef]eng
dcterms.referencesDalli, J.; Serhan, C.N. Specific lipid mediator signatures of human phagocytes: Microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 2012, 120, e60–e72. [CrossRef]eng
dcterms.referencesMitchell, S.; Thomas, G.; Harvey, K.; Cottell, D.; Reville, K.; Berlasconi, G.; Petasis, N.; Erwig, L.; Rees, A.J.; Savill, J.; et al. Lipoxins, Aspirin-Triggered Epi-Lipoxins, Lipoxin Stable Analogues, and the Resolution of Inflammation: Stimulation of Macrophage Phagocytosis of Apoptotic Neutrophils In Vivo. J. Am. Soc. Nephrol. 2002, 13, 2497–2507. [CrossRef]eng
dcterms.referencesPetri, M.H.; Laguna-Fernández, A.; Gonzalez-Diez, M.; Paulsson-Berne, G.; Hansson, G.K.; Bäck, M. The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovasc. Res. 2015, 105, 65–74. [CrossRef]eng
dcterms.referencesNorling, L.V.; Dalli, J.; Flower, R.J.; Serhan, C.N.; Perretti, M. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: Receptor-dependent actions. Arter. Thromb. Vasc. Biol. 2012, 32, 1970–1978. [CrossRef]eng
dcterms.referencesSpite, M.; Norling, L.V.; Summers, L.; Yang, R.; Cooper, D.; Petasis, N.A.; Flower, R.J.; Perretti, M.; Serhan, C.N. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461, 1287–1291. [CrossRef] [PubMed]eng
dcterms.referencesRoig, C.S.; Daemen, M.; Lutgens, E.; Soehnlein, O.; Hartwig, H. Neutrophils in atherosclerosis. A brief overview. Hamostaseologie 2015, 35, 121–127. [CrossRef] [PubMed]eng
dcterms.referencesZhang, P.; Yin, Y.; Wang, T.; Li, W.; Li, C.; Zeng, X.; Yang, W.; Zhang, R.; Tang, Y.; Shi, L.; et al. Maresin 1 mitigates concanavalin A-induced acute liver injury in mice by inhibiting ROS-mediated activation of NF-κB signaling. Free Radic. Biol. Med. 2020, 147, 23–36. [CrossRef]eng
dcterms.referencesZhuang, Y.; Liu, H.; Zhou, X.E.; Verma, R.K.; De Waal, P.W.; Jang, W.; Xu, T.-H.; Wang, L.; Meng, X.; Zhao, G.; et al. Structure of formylpeptide receptor 2-Gi complex reveals insights into ligand recognition and signaling. Nat. Commun. 2020, 11, 885. [CrossRef]eng
dcterms.referencesRomano, M.; Cianci, E.; Simiele, F.; Recchiuti, A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. Eur. J. Pharmacol. 2015, 760, 49–63. [CrossRef] [PubMed]eng
dcterms.referencesRomano, M.; Cianci, E.; Simiele, F.; Recchiuti, A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. Eur. J. Pharmacol. 2015, 760, 49–63. [CrossRef] [PubMed]eng
dcterms.referencesElajami, T.K.; Colas, R.A.; Dalli, J.; Chiang, N.; Serhan, C.N.; Welty, F.K. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016, 30, 2792–2801. [CrossRef]eng
dcterms.referencesMottola, G.; Chatterjee, A.; Wu, B.; Chen, M.; Conte, M.S. Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. PLoS ONE 2017, 12, e0174936. [CrossRef]eng
dcterms.referencesBennett, M.R.; Sinha, S.; Owens, G.K. Vascular Smooth Muscle Cells in Atherosclerosis. Circ. Res. 2016, 118, 692–702. [CrossRef]eng
dcterms.referencesNakayama, A.; Albarrán-Juárez, J.; Liang, G.; Roquid, K.A.; Iring, A.; Tonack, S.; Chen, M.; Müller, O.J.; Weinstein, L.S.; Offermanns, S. Disturbed flow–induced Gs-mediated signaling protects against endothelial inflammation and atherosclerosis. JCI Insight 2020, 5, 140485. [CrossRef]eng
dcterms.referencesFredman, G.; Hellmann, J.; Proto, J.D.; Kuriakose, G.; Colas, R.A.; Dorweiler, B.; Connolly, E.S.; Solomon, R.; Jones, D.M.; Heyer, E.J.; et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 2016, 7, 12859. [CrossRef]eng
dcterms.referencesLee, H.-N.; Surh, Y.-J. Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis. Biochem. Pharmacol. 2013, 86, 759–769. [CrossRef] [PubMed]eng
dcterms.referencesFredman, G.; Ozcan, L.; Spolitu, S.; Hellmann, J.; Spite, M.; Backs, J.; Tabas, I. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc. Natl. Acad. Sci. USA 2014, 111, 14530–14535. [CrossRef] [PubMed]eng
dcterms.referencesDoran, A.C.; Yurdagul, A.; Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 2019, 20, 254–267. [CrossRef] [PubMed]eng
dcterms.referencesCai, B.; Thorp, E.B.; Doran, A.C.; Subramanian, M.; Sansbury, B.E.; Lin, C.-S.; Spite, M.; Fredman, G.; Tabas, I. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc. Natl. Acad. Sci. USA 2016, 113, 6526–6531. [CrossRef]eng
dcterms.referencesRymut, N.; Heinz, J.; Sadhu, S.; Hosseini, Z.; Riley, C.O.; Marinello, M.; Maloney, J.; MacNamara, K.C.; Spite, M.; Fredman, G. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage. FASEB J. 2019, 34, 597–609. [CrossRef]eng
dcterms.referencesHosseini, Z.; Marinello, M.; Decker, C.; Sansbury, B.E.; Sadhu, S.; Gerlach, B.D.; Ramos, R.B.; Adam, A.P.; Spite, M.; Fredman, G. Resolvin D1 Enhances Necroptotic Cell Clearance Through Promoting Macrophage Fatty Acid Oxidation and Oxidative Phosphorylation. Arter. Thromb. Vasc. Biol. 2021, 41, 1062–1075. [CrossRef]eng
dcterms.referencesSchif-Zuck, S.; Gross, N.; Assi, S.; Rostoker, R.; Serhan, C.N.; Ariel, A. Saturated-efferocytosis generates pro-resolving CD11b low macrophages: Modulation by resolvins and glucocorticoids. Eur. J. Immunol. 2011, 41, 366–379. [CrossRef]eng
dcterms.referencesDalli, J.; Winkler, J.W.; Colas, R.A.; Arnardottir, H.; Cheng, C.-Y.C.; Chiang, N.; Petasis, N.A.; Serhan, C.N. Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Potent Immunoresolvents. Chem. Biol. 2013, 20, 188–201. [CrossRef]eng
dcterms.referencesWelty, F.K.; Schulte, F.; Alfaddagh, A.; Elajami, T.K.; Bistrian, B.R.; Hardt, M. Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B 4. FASEB J. 2021, 35, e21448. [CrossRef]eng
dcterms.referencesWu, B.; Mottola, G.; Schaller, M.; Upchurch, G.R.; Conte, M.S. Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications. Mol. Asp. Med. 2017, 58, 72–82. [CrossRef]eng
dcterms.referencesEfremova, O.A.; Starodubov, O.D.; Kamyshnikova, L.A.; Bolkhovitina, O.A.; Obolonkova, N.I. Clinical-functional changes of myocardium after percutaneous coronary interventions in patients with chronic heart failure. Lat. Hipertens. 2019, 14, 256–261.eng
dcterms.referencesEspinoza, R.; Arab, G.; Wiliam, Z.; Carrasquero, L.; Subero, L.; Colina, R.; Ana, T.; Jorge, P.; José, T.; Antonio, V.; et al. Evaluación de la incidencia de trombosis coronaria post Stent, posterior a la comercialización de segundas marcas de Clopidogrel. Hospital Miguel Pérez Carreño. Caracas. Venezuela. AVFT Arch. Venez. Farm. Ter. 2015, 33, 7–12.spa
dcterms.referencesShah, P.K. Inflammation, Neointimal Hyperplasia, and Restenosis. Circulation 2003, 107, 2175–2177. [CrossRef] [PubMed]eng
dcterms.referencesNewby, A.C.; Zaltsman, A.B. Molecular mechanisms in intimal hyperplasia. J. Pathol. 2000, 190, 300–309. [CrossRef]eng
dcterms.referencesConte, M.S.; Desai, T.A.; Wu, B.; Schaller, M.; Werlin, E. Pro-resolving lipid mediators in vascular disease. J. Clin. Investig. 2018, 128, 3727–3735. [CrossRef]eng
dcterms.referencesLiu, G.; Gong, Y.; Zhang, R.; Piao, L.; Li, X.; Liu, Q.; Yan, S.; Shen, Y.; Guo, S.; Zhu, M.; et al. Resolvin E1 attenuates injury-induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration. FASEB J. 2018, 32, 5413–5425. [CrossRef]eng
dcterms.referencesPetri, M.H.; Laguna-Fernandez, A.; Tseng, C.-N.; Hedin, U.; Perretti, M.; Bäck, M. Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int. J. Cardiol. 2015, 179, 370–372. [CrossRef]eng
dcterms.referencesAkagi, D.; Chen, M.; Toy, R.; Chatterjee, A.; Conte, M.S. Systemic delivery of proresolving lipid mediators resolvin D 2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015, 29, 2504–2513. [CrossRef]eng
dcterms.referencesWu, B.; Mottola, G.; Chatterjee, A.; Lance, K.D.; Chen, M.; Siguenza, I.O.; Desai, T.A.; Conte, M.S. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J. Vasc. Surg. 2016, 65, 207–217.e3. [CrossRef]eng
dcterms.referencesWu, B.; Mottola, G.; Chatterjee, A.; Lance, K.D.; Chen, M.; Siguenza, I.O.; Desai, T.A.; Conte, M.S. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J. Vasc. Surg. 2016, 65, 207–217.e3. [CrossRef]eng
dcterms.referencesYang, M.; Chen, Q.; Mei, L.; Wen, G.; An, W.; Zhou, X.; Niu, K.; Liu, C.; Ren, M.; Sun, K.; et al. Neutrophil elastase promotes neointimal hyperplasia by targeting toll-like receptor 4 (TLR4)-NF-κB signalling. Br. J. Pharmacol. 2021, 178, 4048–4068. [CrossRef]eng
dcterms.referencesLi, Y.; Wang, N.; Ma, Z.; Wang, Y.; Yuan, Y.; Zhong, Z.; Hong, Y.; Zhao, M. Lipoxin A4 protects against paraquat-induced acute lung injury by inhibiting the TLR4/MyD88-mediated activation of the NF-κB and PI3K/AKT pathways. Int. J. Mol. Med. 2021, 47, 86. [CrossRef] [PubMedeng
dcterms.referencesLiu, Z.; Qu, M.; Yang, Q.; Chang, Y. Lipoxin A4 ameliorates renal ischaemia–reperfusion-induced acute lung injury in rats. Clin. Exp. Pharmacol. Physiol. 2019, 46, 65–74. [CrossRef] [PubMed]eng
dcterms.referencesLiu, R.; Li, Z.; Wang, Q. Resolvin D1 Attenuates Myocardial Infarction in a Rodent Model with the Participation of the HMGB1 Pathway. Cardiovasc. Drugs Ther. 2019, 33, 399–406. [CrossRef] [PubMed]eng
dcterms.referencesPan, H.; Xue, C.; Auerbach, B.J.; Fan, J.; Bashore, A.C.; Cui, J.; Yang, D.Y.; Trignano, S.B.; Liu, W.; Shi, J.; et al. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human. Circulation 2020, 142, 2060–2075. [CrossRef]eng
dcterms.referencesPan, H.; Xue, C.; Auerbach, B.J.; Fan, J.; Bashore, A.C.; Cui, J.; Yang, D.Y.; Trignano, S.B.; Liu, W.; Shi, J.; et al. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human. Circulation 2020, 142, 2060–2075. [CrossRef]eng
dcterms.referencesFeil, S.; Fehrenbacher, B.; Lukowski, R.; Essmann, F.; Schulze-Osthoff, K.; Schaller, M.; Feil, R. Transdifferentiation of Vascular Smooth Muscle Cells to Macrophage-Like Cells During Atherogenesis. Circ. Res. 2014, 115, 662–667. [CrossRef]eng
dcterms.referencesYang, J.; Li, M.; Hu, X.; Lu, J.; Wang, Q.; Lu, S.; Gao, F.; Jin, S.; Zheng, S. Protectin DX promotes epithelial injury repair and inhibits fibroproliferation partly via ALX/PI3K signalling pathway. J. Cell. Mol. Med. 2020, 24, 14001–14012. [CrossRef]eng
dcterms.referencesZheng, S.; Wang, Q.; D’Souza, V.; Bartis, D.; Dancer, R.; Parekh, D.; Gao, F.; Lian, Q.; Jin, S.; Thickett, D.R. ResolvinD1 stimulates epithelial wound repair and inhibits TGF-β-induced EMT whilst reducing fibroproliferation and collagen production. Lab. Investig. 2018, 98, 130–140. [CrossRef]eng
dcterms.referencesZheng, S.; D’Souza, V.K.; Bartis, D.; Dancer, R.C.; Parekh, D.; Naidu, B.; Gao-Smith, F.; Wang, Q.; Jin, S.; Lian, Q.; et al. Lipoxin A4promotes lung epithelial repair whilst inhibiting fibroblast proliferation. ERJ Open Res. 2016, 2, 00079–02015. [CrossRef]eng
dcterms.referencesFrank, A.; Bonney, M.; Bonney, S.; Weitzel, L.; Koeppen, M.; Eckle, T. Myocardial ischemia reperfusion injury: From basic science to clinical bedside. Semin. Cardiothorac. Vasc. Anesth. 2012, 16, 123–132. [CrossRef]eng
dcterms.referencesBermúdez Arias, D.F. La recuperación del miocardio hibernado mejora el pronóstico de la cardiopatía isquémica metabólica. Gac. Médica Caracas 2020, 113, 19–41.spa
dcterms.referencesWu, M.-Y.; Yiang, G.-T.; Liao, W.-T.; Tsai, A.P.Y.; Cheng, Y.-L.; Cheng, P.-W.; Li, C.-Y.; Li, C.J. Current Mechanistic Concepts in Ischemia and Reperfusion Injury. Cell. Physiol. Biochem. 2018, 46, 1650–1667. [CrossRef] [PubMed]eng
dcterms.referencesChen, Z.; Wu, Z.; Huang, C.; Zhao, Y.; Zhou, Y.; Zhou, X.; Lu, X.; Mao, L.; Li, S. Effect of Lipoxin A4 on Myocardial Ischemia Reperfusion Injury Following Cardiac Arrest in a Rabbit Model. Inflammation 2013, 36, 468–475. [CrossRef] [PubMed]eng
dcterms.referencesChen, X.-Q.; Wu, S.-H.; Zhou, Y.; Tang, Y.-R. Involvement of K+ channel-dependant pathways in lipoxin A4-induced protective effects on hypoxia/reoxygenation injury of cardiomyocytes. Prostaglandins Leukot. Essent. Fat. Acids 2013, 88, 391–397. [CrossRef] [PubMed]eng
dcterms.referencesZheng, J.; Chen, P.; Zhong, J.; Cheng, Y.; Chen, H.; He, Y.; Chen, C. HIF-1α in myocardial ischemia-reperfusion injury. Mol. Med. Rep. 2021, 23, 352. [CrossRef]eng
dcterms.referencesZhao, Q.; Shao, L.; Hu, X.; Wu, G.; Du, J.; Xia, J.; Qiu, H. Lipoxin A4Preconditioning and Postconditioning Protect Myocardial Ischemia/Reperfusion Injury in Rats. Mediat. Inflamm. 2013, 2013, e231351. [CrossRef] [PubMed]eng
dcterms.referencesCheng, Y.; Rong, J. Pro-resolving lipid mediators as therapeutic leads for cardiovascular diseases. Expert Opin. Ther. Targets 2019, 23, 423–436. [CrossRef]eng
dcterms.referencesHalade, G.V.; Norris, P.C.; Kain, V.; Serhan, C.N.; Ingle, K.A. Splenic leukocytes define the resolution of inflammation in heart failure. Sci. Signal. 2018, 11, eaao1818. [CrossRef]eng
dcterms.referencesHalade, G.V.; Kain, V.; Dillion, C.; Beasley, M.; Dudenbostel, T.; Oparil, S.; Limdi, N.A. Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction. ESC Heart Fail. 2020, 7, 1700–1710. [CrossRef]eng
dcterms.referencesTourki, B.; Kain, V.; Pullen, A.B.; Norris, P.C.; Patel, N.; Arora, P.; Leroy, X.; Serhan, C.N.; Halade, G.V. Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure. Mol. Metab. 2020, 31, 138–149. [CrossRef]eng
dcterms.referencesKeyes, K.T.; Ye, Y.; Lin, Y.; Zhang, C.; Perez-Polo, J.R.; Gjorstrup, P.; Birnbaum, Y. Resolvin E1 protects the rat heart against reperfusion injury. Am. J. Physiol. Circ. Physiol. 2010, 299, H153–H164. [CrossRef]eng
dcterms.referencesGilbert, K.; Bernier, J.; Godbout, R.; Rousseau, G. Resolvin D1, a Metabolite of Omega-3 Polyunsaturated Fatty Acid, Decreases Post-Myocardial Infarct Depression. Mar. Drugs 2014, 12, 5396–5407. [CrossRef] [PubMed]eng
dcterms.referencesGilbert, K.; Bernier, J.; Bourque-Riel, V.; Malick, M.; Rousseau, G. Resolvin D1 Reduces Infarct Size Through a Phosphoinositide 3-Kinase/Protein Kinase B Mechanism. J. Cardiovasc. Pharmacol. 2015, 66, 72–79. [CrossRef] [PubMed]eng
dcterms.referencesKain, V.; Ingle, K.A.; Colas, R.A.; Dalli, J.; Prabhu, S.D.; Serhan, C.N.; Joshi, M.D.; Halade, G.V. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J. Mol. Cell. Cardiol. 2015, 84, 24–35. [CrossRef] [PubMed]eng
dcterms.referencesOrr, S.K.; Colas, R.A.; Dalli, J.; Chiang, N.; Serhan, C.N. Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent. Am. J. Physiol. Cell. Mol. Physiol. 2015, 308, L904–L911. [CrossRef]eng
dcterms.referencesPirault, J.; Bäck, M. Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease. Front. Pharmacol. 2018, 9, 1273. [CrossRef]eng
dcterms.referencesSánchez-Hernández, C.D.; Torres-Alarcón, L.A.; González-Cortés, A.; Peón, A.N. Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches. Mediat. Inflamm. 2020, 2020, e8405370. [CrossRef]eng
dcterms.referencesHeinz, J.; Marinello, M.; Fredman, G. Pro-resolution therapeutics for cardiovascular diseases. Prostaglandins Other Lipid Mediat. 2017, 132, 12–16. [CrossRef]eng
dcterms.referencesAyala, J.; López, C.; Hong, A.; Oberto, C.; Paiva, A.; Lares, M. Efecto de los ácidos grasos poliinsaturados (omega 3) sobre la agregación plaquetaria. Lat. Hipertens. 2009, 4, 71–78.spa
dcterms.referencesHasturk, H.; Abdallah, R.; Kantarci, A.; Nguyen, D.; Giordano, N.; Hamilton, J.; Van Dyke, T.E. Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis. Arter. Thromb. Vasc. Biol. 2015, 35, 1123–1133. [CrossRef]eng
dcterms.referencesSalic, K.; Morrison, M.C.; Verschuren, L.; Wielinga, P.Y.; Wu, L.; Kleemann, R.; Gjorstrup, P.; Kooistra, T. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 2016, 250, 158–165. [CrossRef]eng
dcterms.referencesPetri, M.H.; Laguna-Fernandez, A.; Arnardottir, H.; Wheelock, C.E.; Perretti, M.; Hansson, G.K.; Bäck, M. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E-/- mice. Br. J. Pharmacol. 2017, 174, 4043–4054. [CrossRef] [PubMed]eng
dcterms.referencesMakino, Y.; Miyahara, T.; Nitta, J.; Miyahara, K.; Seo, A.; Kimura, M.; Suhara, M.; Akai, A.; Akagi, D.; Yamamoto, K.; et al. Proresolving Lipid Mediators Resolvin D1 and Protectin D1 Isomer Attenuate Neointimal Hyperplasia in the Rat Carotid Artery Balloon Injury Model. J. Surg. Res. 2019, 233, 104–110. [CrossRef] [PubMed]eng
dcterms.referencesThul, S.; Labat, C.; Temmar, M.; Benetos, A.; Bäck, M. Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: A novel biomarker of non-resolving vascular inflammation. Eur. J. Prev. Cardiol. 2017, 24, 903–906. [CrossRef] [PubMed]eng
dcterms.referencesBhatt, D.L.; Steg, P.G.; Miller, M.; Brinton, E.A.; Jacobson, T.A.; Ketchum, S.B.; Doyle, R.T., Jr.; Juliano, R.A.; Jiao, L.; Granowitz, C.; et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N. Engl. J. Med. 2019, 380, 11–22. [CrossRef] [PubMed]eng
dcterms.referencesGromovsky, A.D.; Schugar, R.C.; Brown, A.L.; Helsley, R.N.; Burrows, A.C.; Ferguson, D.; Zhang, R.; Sansbury, B.E.; Lee, R.G.; Morton, R.E.; et al. ∆-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arter. Thromb. Vasc. Biol. 2018, 38, 218–231. [CrossRef]eng
dcterms.referencesSkarke, C.; Alamuddin, N.; Lawson, J.A.; Li, X.; Ferguson, J.F.; Reilly, M.P.; FitzGerald, G.A. Bioactive products formed in humans from fish oils. J. Lipid Res. 2015, 56, 1808–1820. [CrossRef] [PubMed]eng
dcterms.referencesBäck, M.; Yurdagul, A., Jr.; Tabas, I.; Öörni, K.; Kovanen, P.T. Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities. Nat. Rev. Cardiol. 2019, 16, 389–406. [CrossRef]eng
dcterms.referencesZhou, X.; Cai, J.; Liu, W.; Wu, X.; Gao, C. Cysteinyl leukotriene receptor type 1 (CysLT1R) antagonist zafirlukast protects against TNF-α-induced endothelial inflammation. Biomed. Pharmacother. 2019, 111, 452–459. [CrossRef]eng
dcterms.referencesMedina-Leyte, D.; Zepeda-García, O.; Domínguez-Pérez, M.; González-Garrido, A.; Villarreal-Molina, T.; Jacobo-Albavera, L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int. J. Mol. Sci. 2021, 22, 3850. [CrossRef]eng
dcterms.referencesRidker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017, 377, 1119–1131. [CrossRef]eng
dcterms.referencesRidker, P.M.; Everett, B.M.; Pradhan, A.; MacFadyen, J.G.; Solomon, D.H.; Zaharris, E.; Mam, V.; Hasan, A.; Rosenberg, Y.; Iturriaga, E.; et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N. Engl. J. Med. 2019, 380, 752–762. [CrossRef] [PubMed]eng
dcterms.referencesChávez-Castillo, M.; Ortega, A.; Cudris-Torres, L.; Duran, P.; Rojas, M.; Manzano, A.; Garrido, B.; Salazar, J.; Silva, A.; Rojas- Gomez, D.M.; et al. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy? Int. J. Mol. Sci. 2021, 22, 10370. [CrossRef] [PubMed]eng
dcterms.referencesGila-Diaz, A.; Carrillo, G.; Singh, P.; Ramiro-Cortijo, D. Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases. Antioxidants 2021, 10, 933. [CrossRef] [PubMed]eng
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
2022_MDPI_Spec Proresolving Lipid.pdf
Tamaño:
1.18 MB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca